← All trials
NCT06630923
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2023
- Primary completion
- Dec 1, 2025
- Completion date
- Dec 11, 2026
- First posted
- Oct 8, 2024
- Last posted
- Oct 8, 2024
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Democritus University of ThraceLead sponsor
- Democritus University of ThraceSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.